) have proposed a PK/PD (pharmacokinetic/pharmacodynamic) model of the EGP profile that occurs during an intravenous glucose tolerance test (IVGTT); however, this model has also not been validated. The aim of this study was thus to test the Minimal Model, the PK/PD model, and six alternative EGP descriptions on recent model-independent EGP data of 20 subjects obtained with a triple-tracer meal protocol. Model performance was compared in terms of data fit, precision of the estimated parameters, and physiological plausibility. Neither the PK/PD nor the traditional Minimal Model were able to accurately describe EGP data or provide reliable estimates of the indexes. In contrast, one of the new models performed best by showing a good fit and providing accurate and precise estimates of hepatic sensitivity indexes:
) have proposed a PK/PD (pharmacokinetic/pharmacodynamic) model of the EGP profile that occurs during an intravenous glucose tolerance test (IVGTT); however, this model has also not been validated. The aim of this study was thus to test the Minimal Model, the PK/PD model, and six alternative EGP descriptions on recent model-independent EGP data of 20 subjects obtained with a triple-tracer meal protocol. Model performance was compared in terms of data fit, precision of the estimated parameters, and physiological plausibility. Neither the PK/PD nor the traditional Minimal Model were able to accurately describe EGP data or provide reliable estimates of the indexes. In contrast, one of the new models performed best by showing a good fit and providing accurate and precise estimates of hepatic sensitivity indexes: GE L ϭ 0.013 Ϯ 0.001 dl ⅐ kg Ϫ1 ⅐ min Ϫ1 ; SI L ϭ 5.34 Ϯ 0.47 10
Ϫ4
dl ⅐ kg Ϫ1 ⅐ min Ϫ1 per U/ml (42 and 34%, respectively, of total sensitivity indexes GE TOT and SI TOT ). Although this model requires further validation, it has the potential to improve our understanding of the role of the liver in pathophysiological states. glucose kinetics; tracer; meal; insulin resistance THE LIVER IS THE PRIMARY SOURCE of endogenous glucose production (EGP) in the body. When plasma glucose increases, due to an exogenous source (e.g., a meal) insulin secretion is stimulated and EGP is suppressed due to both glucose and insulin signals. In pathological situations, such as diabetes, the control of glucose and insulin on EGP is impaired (14) . Therefore, the ability to assess the individual role of glucose (GE L ) and insulin (S I L ) in the suppression of EGP under physiological conditions would provide insight regarding the contribution of hepatic insulin resistance to glucose intolerance. Calculation of GE L and S I L requires a tracer-labeled meal and a model to mechanistically describe EGP during a meal as a function of glucose and insulin variables.
Recently, Krudys et al. (15) have proposed a PK/PD (pharmacokinetic/pharmacodynamic) model of the EGP profile that occurs during an intravenous glucose tolerance test (IVGTT). It is not known whether this model can assess EGP and hepatic insulin action during a meal. Of note, altohugh this model provides an overall index of insulin action, it does not permit a separate assessment of glucose effectiveness. So far, there have been several unsuccessful attempts to use the labeled IVGTT to assess GE L and S I L by subtracting S I D or GE D (the ability of insulin or glucose, respectively, to stimulate glucose disposal), estimated with the labeled Minimal Model (8, 10) , from S I TOT or GE TOT (the net effect of insulin and glucose on both disposal and production), estimated from the traditional Minimal Model (5). However, the resultant estimates of GE L and S I L are implausible, since the former commonly are greater than the latter, leading to negative values for GE L and S I L (8, 10, 20) . This raises doubts regarding the adequacy of EGP description, which is implicit in the Minimal Model.
In an effort to address these issues, the present study used a virtually model-independent estimate of EGP provided by a triple-tracer meal protocol (3) to test the ability of the PK/PD Model, of the original Minimal Model, and of some new models to accurately describe the known EGP profile and thereby enable simultaneous assessment of S I L and GE L .
MATERIALS AND METHODS

Protocol and Subjects
Twenty normal subjects (age 32 Ϯ 4 yr; BMI 25 Ϯ 1) had a meal (1 g/kg glucose, 10 kcal/kg, 45% carbohydrate, 15% protein, 40% fat) labeled with [1- 13 C]glucose, to segregate the exogenous, i.e., coming from the meal, and the endogenous glucose (data already reported in Ref. 4) . Two additional tracers ( [6, 6- 2 H2]glucose and [6-3 H]glucose), were infused intravenously with the tracer-to-tracee clamp technique (3), i.e., at variable rate mimicking EGP and [1-
13 C]glucose rate of appearance in plasma (R a), respectively. Plasma samples were collected at times Ϫ120, Ϫ30, Ϫ20, Ϫ10, 0, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90, 120, 150, 180, 210, 240, 260, 280, 300, 360 , and 420 min. For details on protocol and measurements we refer to Refs. 3 and 4. After approval from the Mayo Institutional Review Board, all participants gave informed written consent to participate in the study.
EGP Estimates
Virtually model-independent estimates of EGP were obtained by applying the two-compartment model (17) to the clamped tracer-totracee ratio [6,6- 2 H2]glucose/endogenous glucose (TTR) (3) using the equation
where Gend is the plasma concentration of endogenous glucose, V1 is the volume of distribution of the accessible pool and k 12 is the rate constant between the peripheral and the accessible compartment, fixed to 130 ml/kg and 0.07 min Ϫ1 respectively, according to previous studies in normal subjects (17) ; q2 and Q2 are the amounts of [6,6-2 H2]glucose and endogenous glucose in the peripheral compartment, to be evaluated by integrating model equations. As evident from Eq. 1, the estimate of EGP generally depends on the chosen model in terms of both model order (e.g here a two-compartment model) and parameter values. However, the extent of this dependence is minimized in the present study, since the intravenous tracer is infused trying to mimic the expected pattern of EGP and thus to minimize TTR time variations (TTR clamp). When this condition is reached, at least approximately (see RESULTS) , dTTR/dt is close to zero, and a uniform TTR is maintained throughout the system, i.e., q 2/TTR Q2, so that EGP, close to the ratio between the rate of infusion and the TTR, is minimally influenced by the choice of the model.
EGP Models
Eight models were tested. The first is the recently proposed PK/PD Model by Krudys et al. (15) , the second is EGP description incorporated in the traditional Minimal Model (5), and the others are six new models derived from it. PK/PD model. This model is based on the indirect response paradigm, usually adopted in situations when the pharmacodynamic response to a drug is delayed with respect to the time course of its concentration in plasma. It assumes that EGP depends on the amount of releasable glucose in the liver, G L, and an inhibitory function, H2, reflecting the ability of remote insulin to inhibit glucose production (15) :
where k out is the first-order rate constant describing the loss of hepatic glucose into the systemic circulation. GL results from the balance between EGP and hepatic glucose formation, related to plasma glucose concentration, G, through the function H 1:
with k in the apparent zero-order rate constant of hepatic glucose formation. The two indirect response functions H1 and H2 are given by
where G b is basal glucose concentration, IC50 the insulin action producing 50% of maximum inhibition of glucose production and x(t) is insulin action (deviation from basal) on the liver: with p 2 rate constant describing the dynamics of insulin action on glucose production and sk insulin sensitivity, a parameter governing the magnitude of insulin action. Minimal model. The Minimal Model (5) assumes the following description of EGP in terms of glucose concentration and insulin action (10):
where EGP b is the basal EGP, GE L liver glucose effectiveness, G glucose concentration, Gb its basal value, X L liver insulin action (deviation from basal), which follows the dynamic equation:
where k 1 is a rate constant describing the dynamics of insulin action on glucose production and k2 is insulin sensitivity, a parameter governing the magnitude of insulin action.
Model 1.
Since the Minimal Model description of EGP was unable to fit the data well and to provide reliable and precise indexes (see RESULTS ), other models were tested. The first model only considers a direct effect of plasma glucose and insulin concentration on EGP. Model equations are:
Model 2. Model 1 failed to fit data (see RESULTS) , in particular the late EGP suppression 7 h after meal ingestion (Fig. 1, bottom) , since plasma glucose and insulin concentrations have already come back to basal (see Fig. 4, top) . A delayed insulin action can account for this fact. From the physiological point of view, one can interpret the delayed insulin action as a signal surrogating the suppression of FFA level; in fact, insulin lowers FFA concentration, and this makes the liver suppress EGP. Thus, in Model 2, insulin action on EGP is delayed with respect to plasma insulin concentration, as in the Minimal Model (Eq. 7) but, at variance with the Minimal Model, is not multiplied by glucose concentration:
Model 3. Although Model 2 showed an improvement on the PK/PD Model, the Minimal Model, and Model 1 in fitting the data (see RESULTS), parameter estimates were often imprecise and assumes unreliable values. This could be due to the inability of the model to distinguish between the contributions of plasma glucose and delayed insulin action in suppressing glucose production. Therefore Model 3 introduced an additional delay in the insulin action model:
Model 4. This model incorporates the notion (9) that a portal insulin signal controls the rapid suppression of EGP in addition to plasma glucose concentration and delayed insulin. Portal insulin signal is approximated by insulin secretion rate [derived by deconvolution from C-peptide data (18)]:
where SR is insulin secretion rate, SRb is its basal value, and k3 is a parameter governing the magnitude of portal insulin action. Model 5. Model 4 did not provide good results in terms of reliability of estimated parameters (see RESULTS). A possible explanation is that the model is not able to distinguish between the plasma glucose and insulin secretion control, which, apart from the first minutes, show similar pattern (see Fig. 3, top and middle) . We thus tested a model that assumes the control of EGP suppression by portal insulin (i.e., insulin secretion) and delayed insulin, but not by glucose concentration:
with X L and X Sec defined as in Eqs. 10 and 12, respectively. Model 6. Model 5 provided good data fit and parameter estimates (see RESULTS). However, glucose control on EGP is not explicitly, but only implicitly, included in the portal insulin signal. This renders difficult the definition of hepatic glucose effectiveness. To avoid this inconvenience, we exploit the notion that the above-basal insulin secretion during a meal can be modeled as a sum of two components, proportional to the glucose rate of change (through a parameter k GR) and to above-basal glucose concentration (through a parameter kG), respectively (6) . It is of note that in Ref. 6 the latter component is proportional to delayed (ϳ10 min) glucose concentration; conversely, here, since such delay was not identifiable, we used the glucose concentration.
Model equations are
with X L defined as in Eqs. 10 and 15, where kGR is a parameter governing the magnitude of glucose derivative control.
Liver Indexes
Model 6 was selected as the best model to describe EGP data (see RESULTS). Indexes of hepatic glucose effectiveness (GE L ) and insulin sensitivity (SI L ) can be derived from model parameters as follows:
Disposal Indexes
To assess the relative role of production vs. disposal in glucose tolerance, the disposal glucose effectiveness and insulin sensitivity were estimated as follows. First, virtually model-independent estimates of the R a in plasma of ingested glucose were obtained, with an equation similar to Eq. 1, by substituting EGP with Ra, TTR with the ratio [ 
Parameter Estimation
All models were numerically identified by nonlinear least squares (7, 11) 
Statistical Analysis
Model performances were compared on the basis of several criteria (see Ref. 
RESULTS
TTR and EGP
The clamped [6,6-2 H 2 ]glucose/endogenous glucose TTR is shown in Fig. 1 , top, and estimated EGP in Fig. 1 , bottom. TTR is not perfectly constant, but it varies, as expected, in a limited range, thus confirming that the EGP estimate is virtually model independent.
Model Comparison
Weighted residuals of the eight tested models are shown in Fig. 2 . As summarized in Table 1 , all the eight models provided similar WRSS. The PK/PD model and Models 4 and 6 had slightly lower WRSS, essentially due to the higher number of parameters, and their AIC was only modestly higher. The run test supported randomness of residuals only for the PK/PD Model and Models 4, 5, and 6, whereas the Minimal Model and Models 1, 2, and 3 did not provide a good fit of the data. However, the PK/PD Model, like the Minimal Model and Model 1, provided imprecise parameter estimates (CV Ͼ100%). Precision with Model 4 was somewhat better, but parameter values were not plausible for all subjects, since either negative or unrealistically high values were observed for some of them. On the other hand, Models 5 and 6 provided precise (CV ϳ20%) and reliable estimates of the parameters, with no negative values. In summary, the Minimal Model and Models 1, 2, and 3 were excluded due to the non-whiteness of their residuals; the PK/PD Model was excluded due to poor precision (high CV) and Model 4 due to unreliability of parameter estimates. Of the remaining models, Models 5 and 6, Model 5 is physiologically appealing, since the inclusion of insulin secretion allows one to describe portal insulin action; however, glucose control in the liver cannot be estimated independently of portal insulin action (Fig. 3 , middle, where X sec incorporates both glucose and portal insulin). Model 6 overcomes this issue by describing insulin secretion as a sum of two components proportional to glucose rate of change and glucose above basal, respectively. Therefore, we selected Model 6 as the best able to reliably predict the postprandial EGP pattern. bottom. These data indicate that, first, in contrast to the assumption of identical timing of insulin control on the liver and peripheral tissues built in the traditional Minimal Model, in Model 6 the stimulatory effect of insulin on glucose disposal (X D ) peaks at ϳ60 min, whereas insulin action on EGP (X L ) peaks at ϳ150 min. Moreover, the portal insulin control (i.e., the sum of X Der and GE L [G Ϫ Gb]) is greater than the X L , as expected from physiology. It is of note that the addition of a surrogate of the portal insulin (X Der ), which anticipates insulin and glucose patterns, significantly improves the model's ability to predict the rapid suppression of EGP data occurring in the first minutes after the meal (Fig. 2, bottom) . Finally, Model 6 was then used to assess liver glucose effectiveness, GE L , and insulin sensitivity, S I L (Eqs. 16 and 17) . Individual values of these parameters for the 20 subjects are reported in Table 2 together with disposal counterparts  GE  D and S I   D , estimated from the labeled-meal Minimal Model. The relative role of liver and peripheral indexes is summarized in Fig. 4 , indicating that S I L and S I D account for, respectively, ϳ34 and ϳ66% of postprandial insulin action, whereas GE L and GE D account for ϳ42 and 58%, respectively, of postprandial glucose effectiveness.
Liver vs. Disposal Indexes and Insulin Action Profile
DISCUSSION
The efficiency of glucose and insulin control on glucose production plays an important role in glucose homeostasis. It is therefore of interest to quantify the ability of glucose and insulin to suppress glucose production when the system is perturbed by a physiological stimulation such as meal ingestion. The available method to estimate both liver glucose effectiveness and insulin sensitivity consists of using the unlabeled and labeled models to measure, respectively, total (i.e., periphery ϩ liver) and peripheral indexes. Hepatic indexes are then calculated as the difference between the two. Previous studies indicate that indexes derived during an IVGTT using the traditional Minimal Model are unreliable (8, 10, 20) . Caumo et al. (8) suggested that the above inconsistencies are symptoms of model error, related, e.g., to the single-compartment description of glucose kinetics (that they investigated) or to the description of glucose and insulin effect on EGP. In fact, the Minimal Model assumes that insulin action on the liver has the same time course (i.e., the same delay with respect to plasma insulin concentration) of insulin action on glucose disposal. Moreover, EGP suppression includes a term linearly dependent on glucose and a term equal to the product of glucose concentration and insulin action, which means that the effect of insulin on the liver is glucose mediated. Recently, a PK/PD Model of EGP during IVGTT has been also proposed (15) . However, all of these modeling strategies have not been assessed during an oral perturbation, i.e., a meal or an OGTT.
The objective of the present study was to compare the ability of a series of models to predict EGP during a meal: the PK/PD Model (15), the traditional Minimal Model (5), and six evolutions of it. These models were identified on the available model-independent EGP profiles during a meal. Testing the models on these EGP gold standard data instead of plasma glucose concentration data avoids the need to describe glucose disposal and the control of insulin on it and, thus, possible compensation between errors affecting production and disposal. Classical criteria typically used in model selection were adopted: the model's ability to describe the data, the precision of parameter estimates, the physiological plausibility of the parameter values, and model parsimony. Our analysis shows that neither the traditional Minimal nor the PK/PD Model is a reliable description of EGP: the Minimal Model is unable to fit the data, and both the Minimal and PK/PD Models provided imprecise and unreliable parameter estimates. This is not surprising, since both models were originally proposed to describe the rapid changes in glucose and tracer glucose concentrations that occur after intravenous injection of glucose rather than model-independent EGP data, as in the present study. In addition to the PK/PD and the Minimal Models, six new models have been tested. Model 1 assumes a direct control of EGP suppression by plasma glucose and insulin concentration; with Model 2, EGP suppression linearly depends on plasma glucose and a delayed insulin signal; Model 3 is similar to Model 2 but with a more pronounced delay in insulin signal; Model 4, in addition to plasma glucose and delayed insulin controls, incorporates the notion that portal insulin also contributes to inhibit EGP; Model 5 simplifies Model 4 by removing plasma glucose control; and finally, Model 6 assumes that EGP suppression is linearly dependent on plasma glucose concentration, delayed insulin action, and glucose derivative.
The comparison among the eight models is reported in Table  1 and can be summarized as follows.
The Minimal Model and Models 1, 2, and 3 were excluded due to the non-whiteness of their residuals; the PK/PD Model was excluded due to poor precision (high CV) and Model 4 due to unreliability of parameter estimates. Models 5 and 6 showed similar performances in terms of model ability to fit the data and precision of parameter estimates. However, with Model 5 glucose control on the liver cannot be estimated independently from portal insulin action. Not including glucose control on EGP suppression is a questionable assumption and prevents the definition of glucose effectiveness. In fact, in Ref. 19 it is shown that glucose concentration per se has an effect on glucose production. There, 28 subjects participated in either a euglycemia, a sustained-hyperglycemia, or a glucose profile study, with endogenous secretion suppressed by somatostatin and insulin and glucagon concentrations maintained at the same level by exogenous infusion. EGP patterns, calculated with a multiple-tracer technique, were different on the three occasions. Moreover, Model 5 also requires measurement of C-peptide concentration to reconstruct insulin secretion by deconvolution, while Model 6 does not. Nonetheless, a possible explanation of the good performance obtained with Model 5 is that glucose controls EGP in part indirectly by stimulating insulin secretion. Thus, it is likely that neither Model 5 (which assumes no direct effect of glucose on EGP), nor Model 6 (which assumes only a direct effect of glucose on EGP) completely fits the physiology. A model that takes into account both effects (as Model 4) would be the most appropriate. However, the present data do not allow one to distinguish these two components of glucose effectiveness on the liver (see RESULTS) . This problem can be overcome if one interprets parameter GE L as an overall measure of the ability of glucose Nos. in parentheses indicate coefficients of variation (CV%). to inhibit glucose production both directly and indirectly (i.e., by stimulating insulin secretion). Therefore, we propose using Model 6, keeping in mind the above-cited interpretation of this parameter.
The rationale behind this model is that the above-basal insulin secretion can be described with two components: one proportional to the glucose rate of change and the other one proportional to above-basal glucose concentration (6) . Thus, Model 6 provides an estimate of parameter k G , which accounts for both the control of plasma glucose and portal insulin on EGP suppression; parameter k GR , which account for glucose derivative control on the fast suppression of EGP; parameters k 1 , which quantifies the delay between plasma insulin and delayed insulin action, and k 2 , which determines its amplitude. The inclusion of this derivative control significantly improves the ability of the model to fit EGP data in the first 30 min and makes Model 6 superior than other models. However, a comment on available sampling schedule is in order. Our data are frequently sampled in the first 30 min (1 sample each 5 min), and this allowed us to detect the rapid suppression of EGP due to the portal insulin signal; it is likely that a simpler model, such as Model 3, can perform sufficiently well when data are less frequently sampled.
Model 6 differentiates from the traditional Minimal Model in the description of the delayed insulin action. First, it is not multiplied by glucose concentration, which means that glucose and insulin act independently on the liver; then, insulin action on glucose production follows a different time course from the effects of insulin on glucose disposal (Fig. 3, bottom) ; finally the delayed insulin action is described with a two-compartment chain. The superiority of this description compared with the single-compartment delay was evident in all models employing it, including Model 6. In particular, the latter always provided a good fit of the data and reliable and precise parameter estimates (average CV 26%), whereas a model assuming a single delay for insulin action gave imprecise and inaccurate parameter estimates (not shown).
Model 6 also provides indexes of both liver glucose effectiveness, GE L , and insulin sensitivity, S I L , estimated with precision. Their definition follows the traditional formulation of the Minimal Model: i.e., GE L is the ability of glucose to promote EGP suppression, and S I L is the ability of insulin to increment EGP suppression. To understand the relative role of the liver vs. periphery in maintaining glucose homeostasis, indexes of glucose and insulin control on glucose disposal (GE D and S I D ) have been estimated from the hot Minimal Model, identified on tracer glucose data using the R a profile estimated with the TTR clamp technique as known inputs. This permits calculation of GE D and S I D and, thus, of total indexes GE TOT ϭ GE D ϩ GE L and S I TOT ϭ S I D ϩ S I L . Hence, the relative role of the liver vs. periphery can be determined. Model 6 indicates that during a meal GE L and S I L represent 42 and 34% of total glucose effectiveness and insulin action, respectively (Fig. 4) .
Many surrogate indexes of whole body, peripheral, and hepatic insulin resistance have been proposed. For instance, Matsuda and DeFronzo (16) AUC I ) , respectively]. However, the Matsuda-DeFronzo is a basal index of hepatic insulin resistance, since it ignores the change in EGP that occurs as insulin and glucose concentrations change over time. Thus, subjects who have similar "basal" insulin action but a difference in the ability of glucose and/or insulin to suppress glucose production cannot be distinguished. On the other hand, the Abdul-Ghani et al. index assumes that glucose utilization is minimally increased during the initial 30 min after food ingestion and that glucose R a in the first 30 min is zero. These assumptions are rather critical, since results obtained using a triple-tracer approach in 204 subjects showed that glucose R d almost doubles with respect to its basal value in the first 30 min after glucose intake, whereas meal glucose R a peaks right around 30 min after a meal (4).
In conclusion, the present study indicates that the traditional Minimal Model (5) does not accurately predict the pattern of change that occurs after a meal ingestion. In addition, the PK/PD Model (15) is also inadequate to fit EGP data, at least during a meal. Of the six new models proposed, Model 6 best describes EGP data and provides reliable indexes of glucose and insulin control on the liver. Although Model 6 will require further validation, especially in impaired-glucose-tolerant and impaired-fasting-glucose subjects, the present study suggests that it will likely provide an accurate assessment of the pattern of change of endogenous glucose production that occurs after food ingestion and will enable simultaneous assessment of hepatic insulin action and glucose effectiveness.
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